Thierry Facon, MD, PhD, from Hospital Claude Huriez, Lille, France provides an overview of the topics and sessions covered at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. Some of the areas covered at the meetings were the biology and genetics of the disease as well as imaging techniques and minimal residual disease assessment. Prof Facon further discusses the approval of new drugs for multiple myeloma (MM), which include pomalidomide, panobinostat, ixazomib, elotuzumab and daratumumab. According to Prof Facon, it may be possible to cure patients with MM in future. He further discusses PD-1 and PDL-1 drugs and the potential issues around the cost of these new drugs.